伏拉塞替|T6019

價(jià)格	￥397	￥679	￥1070
包裝	2mg	5mg	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:伏拉塞替	英文名稱:Volasertib
CAS:755038-65-4	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.72%	產(chǎn)品類別: 抑制劑
貨號(hào): T6019

Product Introduction

Bioactivity

名稱	Volasertib
描述	Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).
細(xì)胞實(shí)驗(yàn)	Cell proliferation assays were done by incubating cells in the presence of various concentrations of BI 6727 for 72 h and cell growth was assessed by measuring Alamar blue dye conversion in a fluorescence spectrophotometer. Effective concentrations at which cellular growth was inhibited by 50% (EC50) were extrapolated from the dose-response curve fit [1].
激酶實(shí)驗(yàn)	Recombinant human Plk1 (residues 1-603) was expressed as NH2-terminal, GST-tagged fusion protein using a baculoviral expression system and purified by affinity chromatography using glutathione-agarose. Enzyme activity assays for Plk1, Plk2, and Plk3 were done in the presence of serially diluted inhibitor using 20 ng of recombinant kinase and 10 μg casein from bovine milk as substrate. Kinase reactions were done in a final volume of 60 μL for 45 min at 30°C [15 mmol/L MgCl2, 25 mmol/L MOPS (pH 7.0), 1 mmol/L DTT, 1% DMSO, 7.5 μmol/L ATP, 0.3 μCi γ-32P-ATP]. Reactions were terminated by the addition of 125 μL of ice-cold 5% TCA. After transferring the precipitates to MultiScreen mixed ester cellulose filter plates, plates were washed with 1% TCA and quantified radiometrically. Dose-response curves were used for calculating IC50 values. To establish a kinase selectivity profile, additional kinase assays were done by contract research organizations or reagents were purchased from commercial sources and assays were done according to the supplier's instructions. Appropriate positive and negative controls were included in the assay design [1].
動(dòng)物實(shí)驗(yàn)	Female BomTac:NMRI-Foxn1nu mice were grafted s.c. with 2 × 10^6 HCT 116 human colon carcinoma cells (ATCC CCL-247), 1 × 10^6 NCI-H460 non–small cell lung cancer cells (ATCC HTB-177), or CXB1 human colon carcinoma tumor pieces derived from patient material by serial transplantation in nude mice. When tumors had reached a volume of ～50 to 100 mm^3, animals were randomized into treatment and control groups of 10 mice each. BI 6727 was formulated in hydrochloric acid (0.1 N), diluted with 0.9% NaCl, and injected i.v. into the tail vein at the indicated dose and schedule. For oral treatment, BI 6727 was resuspended in 0.5% Natrosol 250 hydroxyethyl-cellulose and given intragastrally via gavage needle. An administration volume of 10 mL per kilogram of body weight was used for both administration routes. Tumor volumes were determined thrice a week using a caliper. The results were converted to tumor volume (mm^3) by the formula length × width2 × π/6. The weight of the mice was determined as an indicator of tolerability on the same days. Median tumor volumes on the last day of the experiment were used to calculate treated versus control values (= tumor volume treated mice × 100/tumor volume control mice) [1].
體外活性	Volasertib（BI 6727）有效抑制了Plk1及其兩個(gè)密切相關(guān)的激酶Plk2和Plk3（IC50值分別為0.87、5、56 nmol/L）。BI 6727能夠抑制來(lái)自多種癌癥組織的多種細(xì)胞系的增殖，包括結(jié)腸癌（HCT 116，EC50=23 nmol/L）和肺癌（NCI-H460，EC50=21 nmol/L），黑色素瘤（BRO，EC50=11 nmol/L）以及血液癌癥（GRANTA-519，EC50=15 nmol/L；HL-60，EC50=32 nmol/L），其EC50值范圍為11至37 nmol/L [1]。BI 6727對(duì)NB TICs顯示出nM級(jí)別的活性，EC50為21 nmol/L，并具有出色的選擇性，SKPs的EC50為2.8 μmol/L [2]。在測(cè)試的所有40種細(xì)胞系中，Volasertib抑制了增殖，平均半最大抑制濃度為313 nmol/l（范圍：4-5000 nmol/l）[3]。
體內(nèi)活性	BI 6727具有良好的理化性質(zhì)和藥代動(dòng)力學(xué)性質(zhì)，能夠進(jìn)行靜脈注射(i.v.)以及口服制劑的體內(nèi)測(cè)試，為給藥計(jì)劃提供了靈活性。此外，BI 6727在多種癌癥模型中顯示出顯著的抗腫瘤活性，包括對(duì)紫杉醇耐藥性結(jié)腸癌模型[1]。Volasertib對(duì)RMS-1泡狀肌肉瘤移植瘤表現(xiàn)出高度活性，實(shí)現(xiàn)了100%的腫瘤消退。其活性與G2/M期阻滯的完全和持久相關(guān)，并隨后引起凋亡細(xì)胞死亡。Volasertib與長(zhǎng)春新堿表現(xiàn)出協(xié)同作用，但與依托泊苷表現(xiàn)出拮抗效應(yīng)[3]。
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 14 mg/mL (22.62 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble)
關(guān)鍵字	GRANTA-519 \| Raji \| BRO \| Inhibitor \| ATP-competitive \| Volasertib \| mitotic \| HL-60 \| BI-6727 \| orally \| Polo-like Kinase (PLK) \| HCT 116 \| arrest \| NCI-H460 \| inhibit \| BI6727 \| dihydropteridinone \| Apoptosis \| THP-1
相關(guān)產(chǎn)品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相關(guān)庫(kù)	抑制劑庫(kù) \| 抗癌活性化合物庫(kù) \| 抗癌上市藥物庫(kù) \| 經(jīng)典已知活性庫(kù) \| 抗衰老化合物庫(kù) \| FDA 上市激酶抑制劑庫(kù) \| 藥物功能重定位化合物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字：伏拉塞替|||BI 6727|TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.2651萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營(yíng)模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊(cè)資本：566.2651萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑，藥物篩選化合物庫(kù)，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

2'-O-(2-甲氧乙基)腺苷|TNU0047

￥258

辛酸|T6157

￥233

木瓜酶|T19503

￥150